Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Cancers|June 26, 2026
Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient DataLorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, et al.
Journal of Pharmacy Practice|June 15, 2021
Hospital Pharmacy Response to Covid-19 Pandemic in Italy: What We Learned From the First Outbreak WaveVera Damuzzo, Riccardo Bertin, Daniele Mengato, et al.
Cureus|September 29, 2022
The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial CarcinomaAndrea Messori, Melania Rivano, Luca Cancanelli, et al.
Cytometry. Part B, Clinical Cytometry|November 27, 2014
Complexity and challenges in defining myeloid-derived suppressor cellsVera Damuzzo, Laura Pinton, Giacomo Desantis, et al.
Cytometry. Part B, Clinical Cytometry|December 16, 2014
Complexity and challenges in defining myeloid-derived suppressor cellsVera Damuzzo, Laura Pinton, Giacomo Desantis, et al.
Cancers|July 13, 2024
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, et al.
International Journal of Technology Assessment in Health Care|July 14, 2017
CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITALAlberto Russi, Vanna Chiarion-Sileni, Vera Damuzzo, et al.
Journal of Chemotherapy (Florence, Italy)|April 12, 2017
Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational studyAlberto Russi, Vera Damuzzo, Marco Chiumente, et al.
Cancers|March 29, 2023
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 AnalysesAndrea Messori, Vera Damuzzo, Melania Rivano, et al.
Translational Lung Cancer Research|June 15, 2026
Long-term outcomes of ALK inhibitors in metastatic <i>ALK</i>-positive non-small cell lung cancer: an updated indirect comparison using reconstructed patient-level dataAndrea Ossato, Vera Damuzzo, Luna Del Bono, et al.
Pageof 4